

Appendices

Supplemental Table 1. Estimated new and review patient load, Australia, 2020.

	Initial patients					Review patients					
	Prop. Likely to see neurologist	Initial encounter duration, min.	Incidence rate per 100,000 person-years	Initial case load	Initial case load, hours	Prop. likely to see neurologist	Review encounter frequency	Review encounter duration, min.	Prevalence per 100,000 persons	Review case load	Review case load, hours
Autoimmune encephalitis	30%	60	0.80 ¹	61.69	61.69	30%	3	30	13.70 ¹	3,169.38	554.64
Nervous system cancers	60%	60	7.20 ²	1,110.44	1,110.44						
Traumatic brain injury	5%	60	939.00 ³	12,068.31	12,068.31	5%	1	30	12111.08 ⁴	155,655.31	77,827.66

CIDP and chronic neuropathies	100%	40	0.33 ⁵	84.83	56.55	100%	2	20	2.81 ⁵	1,444.60	481.53
Encephalitis, infectious	5%	60	5.00 ²	64.26	64.26	0%					
Epilepsy	100%	40	61.44 ⁶	15,792.91	10,528.61	50%	2	20	638.00 ⁶	163,995.37	54,665.12
Functional neurological disorders	100%	60	29.50 ⁷	7,582.86	7,582.86	20%	2	30	37.20 ⁷	3,824.84	286.86
Guillain-Barre	100%	40	1.11 ⁸	285.32	190.21	50%	2	20	1.90 ⁹	488.39	24.42
Migraine	15%	40	810.00 ¹⁰	31,231.09	20,820.73	15%	2	20	15000.00 ¹¹	1,156,707.1	385,569.05
Motor neurone disease	100%	40	0.78 ¹²	200.50	133.66	100%	3	30	4.50 ¹²	3,470.12	1,735.06

Multiple sclerosis and neuroimmunology	100%	60	3.30 ²	848.25	848.25	100%	2	30	103.70 ¹³	53,311.35	26,655.67
Myasthenia gravis	100%	60	0.53 ¹⁴	136.23	136.23	100%	2	30	7.77 ¹⁴	3,994.50	1,997.25
Myopathies, inflammatory	50%	60	0.80 ¹⁵	102.56	102.56	0%					
Neurocognitive disorders	20%	60	923.06 ¹⁶ (60+yo)	10,615.09	10,615.09	10%	1	30	13402.35 ¹⁷ (65+yo)	57,577.14	28,788.57
Optic neuritis	50%	60	3.70 ¹⁸	475.54	475.54	0%					
Pain (neuropathic, vertebrogenic)	5%	40	820.00 ¹⁹	10,538.89	7,025.92	5%	2	20	9,800.00 ²⁰	2,519,051.0 9	83,968.37

Parkinson's disease & Movement disorders	90%	60	13.43 ²¹	3,106.92	3,106.92	90%	2	60	106.28 ²¹	124,574.40	124,574.40
Peripheral nerve injuries	50%	60	13.90 ²²	1,786.47	1,786.47	0%					
Peripheral neuropathy/ neuritis	10%	60	790.00 ²³	20,306.64	20,306.64	10%	2	30	2360.00 ^{23 24}	121,325.73	60,662.86
Sleep disorders						5%	1	20	6947.17 ²⁵	89,287.18	29,762.39
Obstructive sleep apnoea	5%	40	139.2 ^{0 26}	1,789.04	1,192.69						
Insomnia	5%	40	1842.95 ²⁷ (35+yo)	12,933.84	8,622.56						

Spinal cord injury	5%	60	1.45 ²⁸	372.72	18.64	0%						
Stroke	95%	40	159.00 ²⁹	38,762.54	36,824.41	5%	1	20	1316.30 ²⁹	2,043.50	681.17	
Transverse myelitis	95%	60	3.10 ³⁰	796.84	757.00	0%						
Trigeminal neuralgia	50%	40	9.90 ³¹	2,544.76	1,272.38	50%	4	20	9.90 ³²	7,922.16	2,640.72	
Total				172,099.0	134,447.2					2,200,696.2	0	880,875.74
Abbreviations: CIDP= Chronic inflammatory demyelinating												

polyradiculoneuro pathy.											
-----------------------------	--	--	--	--	--	--	--	--	--	--	--

Supplemental Table 2. Estimated new and review patient load, Australia, 2034. This estimate is based on the current epidemiological data, projected for the forecasted population growth.

	Initial patients					Review patients					
	Prop. likely see neurologist	Consult duration, min.	Incidence rate	Initial case load	Initial case load, hours	Prop. likely see neurologist	Consult frequency	Consult duration, min.	Prevalence	Review case load	Review case load, hours
Autoimmune encephalitis	30%	60	0.80 ¹	78.52	78.52	30%	3	30	13.70 ¹	4,033.87	705.93
Nervous system cancers	60%	60	7.20 ²	1,413.33	1,413.33						0.00
Traumatic brain injury	5%	60	939.00 ³	15,360.11	15,360.11	5%	1	30	12111.08 ⁴	198,112.46	99,056.23

CIDP and chronic neuropathies	100%	40	0.33 ⁵	107.96	71.97	100%	2	20	2.81 ⁵	1,838.63	612.88
Encephalitis, infectious	5%	60	5.00 ²	81.79	81.79	0%					
Epilepsy	100%	40	61.44 ⁶	20,100.64	13,400.43	50%	2	20	638.00 ⁶	208,727.38	69,575.79
Functional neurological disorders	100%	60	29.50 ⁷	9,651.19	9,651.19	20%	2	30	37.20 ⁷	4,868.12	365.11
Guillain-Barre	100%	40	1.11 ⁸	363.15	242.10	50%	2	20	1.90 ⁹	621.60	31.08
Migraine	15%	40	810.00 ¹⁰	39,749.81	26,499.87	15%	2	20	15000.00 ¹ 1	1,472,215.0 5	490,738.35
Motor neurone disease	100%	40	0.78 ¹²	255.18	170.12	100%	3	30	4.50 ¹²	4,416.65	2,208.32

Multiple sclerosis and neuroimmunology	100%	60	3.30 ²	1,079.62	1,079.62	100%	2	30	103.70 ¹³	67,852.76	33,926.38
Myasthenia gravis	100%	60	0.53 ¹⁴	173.39	173.39	100%	2	30	7.77 ¹⁴	5,084.05	2,542.02
Myopathies, inflammatory	50%	60	0.80 ¹⁵	130.54	130.54	0%					
Neurocognitive disorders	20%	60	923.06 ¹⁶ (60+yo)	13,510.48	13,510.48	10%	1	30	13402.35 ¹ 7 (65+yo)	73,282.11	36,641.05
Optic neuritis	50%	60	3.70 ¹⁸	605.24	605.24	0%					
Pain (neuropathic, vertebrogenic)	5%	40	820.00 ¹⁹	13,413.51	8,942.34	5%	2	20	9,800.00 ²⁰	320,615.72	106,871.91

Parkinson's & Movement disorders	90%	60	13.43 ²¹	3,954.37	3,954.37	90%	2	60	106.28 ²¹	124,574.40	124,574.40
Peripheral nerve injuries	50%	60	13.90 ²²	2,273.75	2,273.75	0%					
Peripheral neuropathy/ neuritis	10%	60	790.00 ²³	25,845.55	25,845.55	10%	2	30	2360.00 ²³ 24	154,419.00	77,209.50
Sleep disorders						5%	1	20	6947.17 ²⁵	113,641.49	37,880.50
Obstructive sleep apnoea	5%	40	139.20 ²⁶	2,277.03	1,518.02						
Insomnia	5%	40	1842.95 27 (35+yo)	16,461.72	10,974.48						

Spinal cord injury	5%	60	1.45 ²⁸	23.72	23.72	0%					
Stroke	95%	40	159.00 ²⁹	49,417.07	32,944.71	5%	1	20	1316.30 ²⁹	2,600.90	866.97
Transverse myelitis	95%	60	3.10 ³⁰	963.48	963.48	0%					
Trigeminal neuralgia	50%	40	9.90 ³¹	1,619.44	1,079.62	50%	4	20	9.90 ³²	10,083.04	3,361.01
Total				219,041.4	171,119.6					2,766,987.2	1,087,167.
				7	3					2	43
Abbreviations: CIDP= Chronic inflammatory demyelinating polyradiculoneuropathy.											

Supplemental Table 3. Estimating number of Active Neurology Consultant Fellows of the RACP, practicing in Adult Neurology in Australia from RACP Internal

Membership Reports.

	2020 ³³	2019 ³⁴
RACP Members	27,843	26,761
In Australia	23,303 (83.7%)	22,330 (83.4%)
RACP Fellows	18,863 (67.8%)	18,071 (67.5%)
Active RACP Fellows	17,160 (61.6%) (91.0% of Fellows)	16,435 (61.4%) (91.0% of Fellows)
Australian RACP Fellows	15,641 (82.9%)	14,919 (66.8%)
Australian Active RACP Fellows	14,436 (51.8%)	13,774 (51.5%)
Australian Active RACP Fellows	14,436	13,774
Major Urban	12,685 (87.9%)	12,133 (88.1%)
Inner Regional	1,235 (8.6%)	1,150 (8.3%)
Outer Regional	445 (3.1%)	424 (3.1%)

Remote	70 (0.5%)	65 (0.5%)
Neurology	960	901
Adult Neurology practitioners (including non-fellows)	852 (88.8%)	800 (88.8%)
Neurology Fellows	756 (78.8%)	710 (78.8%)
Neurology RACP Fellows x % in Australia x % Active x % Adult Neurology	756x83.7%x91.0%x88.8%	710x83.4%x91.0%x88.8%
Number of Active, Neurology RACP Fellows working in Australia who work in Adult Neurology (does not include neurology trainees)	511	479

Supplemental Table 4. Allocation of model parameters based on data from MBA, RACP, Medical Deans ANZ Student Statistics, and ANZAN survey.

	μ	α	M(0)	λ_m	T(0)	λ_t	E(0)	λ_e	L(0)	s_1	S(0)	$s_2 + \gamma$	Total neurologists
2020	0.38	3,637	4,155	0.44	106	47	208	35	299	3.5 (0.9% PY)	4	0.46	617
2019	0.53	3,693	3,996	0	96	47	195		280		4	0.40	575
2018	0.48	3,475	4,052	2	90	45	193		277		3		564
2017		3,569	3,569		83	22	187		267		3		540
2016		3,547				1							422
2015		3,437				25							421

Number of Advanced Physician Trainees in neurology (T); Number of Early-Career neurology consultants (E): from the 2020 ANZAN survey; Number of Mid/Late-Career neurology consultants (L): from the 2020 ANZAN survey; Number of semi-retired (S): From the 2020 ANZAN survey; Immigration (μ): μ is derived from data from the Medical Board of Australia international medical graduate applications; Rate of Basic Physician Trainees admitted into Advanced Neurology Trainees (λ_m): from ANZAN records; Rate of Retirement: from RACP annual reports; Rates of transition from Advanced Neurology Trainee to Early-Career Neurologist (λ_t) and from Early-Career Neurologist to Mid/Late-Career Neurologist (λ_e) are dynamically estimated within the

function by the Total Neurology Consultant numbers and the values of the other model components; Rate of conversion from semi-retired to retired (s2) and rate of conversion to retired, emigrated, and left neurology (γ).

Supplemental Table 5. ANZAN survey respondent characteristics.

	n (%)	
	Total survey sample (n=738)	Australian, Active, Working in last 12 months, Works with adults (n=577)
Sex		
Male	472 (64.0%)	370 (64.1%)
Female	265 (35.9%)	206 (35.7%)
Unspecified	1 (0.1%)	1 (0.2%)

ANZAN member		
No	6 (0.8%)	5 (0.9%)
Yes	732 (99.2%)	572 (99.1%)
Working status		
Active	714 (96.8%)	577 (100%)
TNIP	9 (1.2%)	
Semi-retired	13 (1.8%)	
Retired	2 (0.3%)	
Country of secondary school		
Australia	236 (68.2%)	214 (72.8%)
New Zealand	30 (8.7%)	9 (3.1%)
Other	80 (23.1%)	71 (24.2%)
(Missing)	(392 (53.1%))	(283 (49.1%))
Country of medical school		

Australia	378 (70.9%)	332 (76.2%)
New Zealand	42 (7.9%)	8 (1.8%)
Other	113 (21.2%)	96 (22.0%)
(Missing)	(205 (27.8%))	(141 (24.4%))
Country of specialist training		
Australia	362 (81.0%)	325 (87.8%)
New Zealand	25 (5.6%)	3 (0.8%)
Other	60 (13.4%)	42 (11.4%)
(Missing)	(291 (39.4%))	(207 (35.9%))
Country of current work		
Australia	649 (87.9%)	577 (100%)
New Zealand	58 (7.9%)	
Other	31 (4.2%)	

Adult/paediatric neurology		
Neither	29 (3.9%)	14 (2.4%)
Adult only	692 (93.8%)	558 (96.7%)
Paediatric only	11 (1.5%)	0 (0%)
Both	6 (0.8%)	5 (0.9%)
Advanced physician trainee?		
No	565 (76.6%)	447 (77.5%)
Yes	173 (23.4%)	130 (22.5%)
	Mean (SD; range)	
Age (missing 2)	44.68 (12.43; 20-85)	44.26 (11.96; 26-84)
Abbreviations: ANZAN = Australia New Zealand Association of Neurologists; TNIP = Temporarily not in practice.		

Supplemental Table 6. Neurology specialisations and mean patient numbers/FTE fractions from 2020 ANZAN survey, restricted to 577 respondents who were active, adult neurologists, working in Australia.

	Number of practitioners who work in a neurological specialty (out of 577)?	Number of NEW encounters per clinic (0.1 FTE) and week for specialisation	Number of REVIEW encounters seen per clinic (0.1 FTE) and week for specialisation	Number of inpatients seen per 0.1 FTE for specialisation	Average total FTE (public+private) for each specialisation
	n (percentage)	mean (SD; range)			
Epilepsy					
	138 (23.9%)	1.84 (1.89; 0-12)	4.28 (5.71; 0-45)	1.12 (1.85; 0-12)	0.32 (0.27; 0-1)
MS/neuroimmunology					
	133 (23.1%)	1.16 (1.19; 0-6)	3.46 (3.67; 0-20)	0.42 (1.31; 0-12)	0.21 (0.17; 0-1)
Neuromuscular					
	101 (17.5%)	1.55 (1.86; 0-10)	2.99 (3.94; 0-24)	0.20 (0.68; 0-5)	0.17 (0.15; 0.1-0.9)
Movement disorders					
	108 (18.7%)	1.66 (1.83; 0-10)	4.11 (6.35; 0-50)	0.57 (1.64; 0-10)	0.27 (0.23; 0-1)

Stroke					
	153 (26.5%)	1.50 (2.93; 0-30)	1.86 (2.82; 0-20)	3.81 (6.02; 0-36)	0.33 (0.28; 0-1)
Clinical neurophysiology					
	154 (26.7%)	5.01 (5.14; 0-32)	0.33 (1.22; 0-10)	0.53 (1.42; 0-10)	0.24 (0.22; 0-1)
Cognitive/behavioural neurology					
	43 (7.5%)	1.02 (1.18; 0-5)	2.09 (3.56; 0-20)	0.77 (2.07; 0-12)	0.17 (0.08; 0.1-0.3)
Headache					
	94 (16.3%)	1.54 (1.56; 0-6)	3.35 (5.46; 0-45)	0.49 (1.20; 0-6)	0.21 (0.22; 0-1)
Neuro-ophthalmology					
	32 (5.6%)	0.91 (1.28; 0-5)	1.66 (2.18; 0-7)	0.16 (0.37; 0-1)	0.15 (0.14; 0-0.5)
Neuro-otology					
	29 (5.0%)	2.03 (2.85; 0-12)	3.17 (5.99; 0-30)	0.28 (0.53; 0-2)	
General neurology					
	387 (67.1%)	2.65 (3.83; 0-40)	4.94 (6.95; 0-60)	2.82 (4.61; 0-30)	0.42 (0.31; 0-1)

Other					
	17 (3.0%)	1.94 (3.29; 0-12)	2.82 (5.78; 0-22)	0.35 (1.22; 0-5)	0.2 (0.13; 0.1-0.5)

Supplemental Table 7. Estimation of supply and demand of neurological care in Australia in 2020 and 2034 including interventions.

	2020	2034	+5 neurologists per year, 2022-2031	+10 neurologists per year, 2022-2031	+20 neurologists per year, 2022-2031
Supply of neurological care					
Neurologists	620	896	935	973	1051
Weeks/year	43	43	43	43	43
Initial Pts per week (2.75 per clinic) ^a	16.56	16.56	16.56	16.56	16.56

Review Pts per week (5.49 per clinic) ^a	32.94	32.94	32.94	32.94	32.94
Initial Pts/year ^b	441,489.60	638,023.68	665,794.80	692,853.84	748,396.08
Review Pts/year ^c	878,180.40	1,269,112.32	1,324,352.70	1,378,176.66	1,488,657.42
Demand for neurological care ^d					
Initial encounters/year	172,099.08	219,041.47	219,041.47	219,041.47	219,041.47
Review encounters/year	2,200,696.20	2,766,987.22	2,766,987.22	2,766,987.22	2,766,987.22

Difference between supply and demand of neurological care ^d					
Initial encounters/year	Demand fully met	Demand fully met	Demand fully met	Demand fully met	Demand fully met
Review encounters/year	-1,322,515.80	-1,497,874.90	-1,442,634.52	-1,388,810.56	-1,278,329.80
Supply vs Demand based on Australia national disease-specific patient counts ^d , 10%					

Initial allocation first, then remaining capacity to Review					
Initial encounters/year	-154,889.17	-197,137.32	-197,137.32	-197,137.32	-197,137.32
Review encounters/year	-898,236.11	-881,755.37	-798,743.87	-717,860.87	-551,837.87
<p>a. Initial and review patient numbers derived from 2020 ANZAN Member Survey.</p> <p>b. Patient capacity for Initial encounters estimated as: Number of neurologists \times FTE fraction \times Weeks/year \times # Initial Patients per week.</p> <p>c. Patient capacity for Review encounters estimated as: Number of neurologists \times FTE fraction \times Weeks/year \times # Review Patients per week.</p> <p>d. Estimated new and review patient load based on disease-specific patient counts as in Supplemental Table 1.</p>					

Supplemental Table 8. Estimation of durational supply and demand for neurological care in Australia, 2020 to 2034 with intervention scenarios.

	2020	2034	+5 neurologists per year, 2022-2031	+10 neurologists per year, 2022-2031	+20 neurologists per year, 2022-2031
Supply of neurological care					
Neurologists	620	896	935	973	1051
Weeks/year	43	43	43	43	43
Initial Pts per week (2.75 per clinic) ^a	16.56	16.56	16.56	16.56	16.56
Review Pts per week (5.49 per clinic) ^a	32.94	32.94	32.94	32.94	32.94
Initial encounters/year ^b	441,489.60	638,023.68	665,794.80	692,853.84	748,396.08

Review encounters/year ^c	878,180.40	1,269,112.32	1,324,352.70	1,378,176.66	1,488,657.42
Patient Durational Supply, Hours (60 min per new, 30 min per review)					
Initial encounters/year ^b	344,361.89	497,658.47	519,319.94	540,426.00	583,748.94
Review encounters/year ^c	342,490.36	494,953.80	516,497.55	537,488.90	580,576.39

Durational demand for neurological care ^d					
Initial encounters/year	134,447.29	171,878.64	171,878.64	171,878.64	171,878.64
Review encounters/year	880,875.74	1,087,167.43	1,087,167.43	1,087,167.43	1,087,167.43
Supply vs 1-year average Durational Demand based on Australia national disease-specific patient counts ^d .					

Initial encounters/year	Demand fully met	Demand fully met	Demand fully met	Demand fully met	Demand fully met
Review encounters/year	-538,385.39	-592,213.62	-570,669.87	-549,678.53	-506,591.03
Supply vs 1-year average Durational Demand based on Australia national disease-specific patient counts ^d , 10% Initial allocation first, then remaining					

capacity to Review					
Initial encounters/year	-121,002.56	-154,007.67	-154,007.67	-154,007.67	-154,007.67
Review encounters/year	-207,468.23	-111,667.12	-68,461.89	-26,364.50	Demand fully met
<p>a. Initial and review patient numbers derived from 2020 ANZAN Member Survey.</p> <p>b. Patient capacity for Initial encounters estimated as: Number of neurologists x FTE fraction x Weeks/year x # Initial Patients per week.</p> <p>c. Patient capacity for Review encounters estimated as: Number of neurologists x FTE fraction x Weeks/year x # Review Patients per week.</p> <p>d. Estimated new and review patient load based on disease-specific patient counts as in Supplemental Table 1.</p>					

Supplemental Table 9. Neurology patient supply and demand estimation, regional Australia, 2020 to 2034, updated prevalence and incidence-based demand estimates with intervention scenarios.

	2020	2034	+2 neurologists per year, 2022-2031	+5 neurologists per year, 2022-2031	+10 neurologists per year, 2022-2031
Supply of neurological care					
Neurologists	25	33	46	65	97
Weeks/year	43	43	43	43	43
Initial Pts per week (2.75 per clinic) ^a	16.56	16.56	16.56	16.56	16.56
Review Pts per week (5.49 per clinic) ^a	32.94	32.94	32.94	32.94	32.94

Initial encounters/year ^b	17,802.00	23,498.64	32,755.68	46,285.20	69,071.76
Review encounters/year ^c	35,410.50	46,741.86	65,155.32	92,067.30	137,392.74
Demand for neurological care ^d					
Initial encounters/year	53,350.71	67,902.86	67,902.86	67,902.86	67,902.86
Review encounters/year	682,215.82	857,766.04	857,766.04	857,766.04	857,766.04
Supply vs Demand based on Australian national disease-					

specific patient counts ^d .					
Initial encounters/year	-35,548.71	-44,404.22	-35,147.18	-21,617.66	Demand fully met
Review encounters/year	-646,805.32	-811,024.18	-792,610.72	-765,698.74	-720,373.30
Supply vs Demand based on Australian national disease-specific patient counts ^d , 10% Initial allocation first, then remaining capacity to Review					

Initial encounters/year	-48,015.64	-61,112.57	-61,112.57	-61,112.57	-61,112.57
Review encounters/year	-634,356.88	-794,315.82	-766,645.32	-726,203.82	-658,091.82
<p>a. Initial and review patient numbers derived from 2020 ANZAN Member Survey.</p> <p>b. Patient capacity for Initial encounters estimated as: Number of neurologists x FTE fraction x Weeks/year x # Initial Patients per week.</p> <p>c. Patient capacity for Review encounters estimated as: Number of neurologists x FTE fraction x Weeks/year x # Review Patients per week.</p> <p>d. Estimated new and review patient load based on disease-specific patient counts as in Supplemental Table 1.</p>					

Supplemental Table 10. Estimation of durational supply and demand for neurological care in regional Australia, 2020 to 2034, with intervention scenarios.

	2020	2034	+2 neurologists per year, 2022-2031	+5 neurologists per year, 2022-2031	+10 neurologists per year, 2022-2031
--	------	------	-------------------------------------	-------------------------------------	--------------------------------------

Supply of neurological care					
Neurologists	25	33	46	65	97
Weeks/year	43	43	43	43	43
Initial Pts per week (2.75 per clinic) ^a	16.56	16.56	16.56	16.56	16.56
Review Pts per week (5.49 per clinic) ^a	32.94	32.94	32.94	32.94	32.94
Initial encounters/year ^b	17,802.00	23,498.64	32,755.68	46,285.20	69,071.76
Review encounters/year ^c	35,410.50	46,741.86	65,155.32	92,067.30	137,392.74

Patient Durational Supply, Hours (60 min per new, 30 min per review)					
Initial encounters/year ^b	17,802.00	23,498.64	32,755.68	46,285.20	69,071.76
Review encounters/year ^c	17,705.25	23,370.93	32,577.66	46,033.65	68,696.37
Durational demand for neurological care ^d					
Initial encounters/year	13,885.56	18,328.94	25,549.43	36,102.46	53,875.97
Review encounters/year	13,810.10	18,229.33	25,410.57	35,906.25	53,583.17

Supply vs 1-year average Durational Demand based on Australia national disease-specific patient counts ^d .					
Initial encounters/year	-27,793.10	-34,718.15	-27,497.66	-16,944.63	Demand fully met
Review encounters/year	-259,261.39	-318,792.58	-311,611.33	-301,115.66	-283,438.73
Supply vs 1-year average Durational Demand based on Australia national					

disease-specific patient counts ^d , 10% Initial allocation first, then remaining capacity to Review					
Initial encounters/year	-37,510.79	-47,742.38	-47,742.38	-47,742.38	-47,742.38
Review encounters/year	-249,543.69	-305,768.35	-291,366.61	-270,317.91	-234,867.47
<p>a. Initial and review patient numbers derived from 2020 ANZAN Member Survey.</p> <p>b. Patient capacity for Initial encounters estimated as: Number of neurologists \times FTE fraction \times Weeks/year \times # Initial Patients per week.</p> <p>c. Patient capacity for Review encounters estimated as: Number of neurologists \times FTE fraction \times Weeks/year \times # Review Patients per week.</p> <p>d. Estimated new and review patient load based on disease-specific patient counts as in Supplemental Table 1.</p>					

Supplemental Table 11. Estimation of patient supply/demand for Australia, 2020, assessing different fractions of Initial encounter demand allocation.

		Allocation of Initial demand of neurology care before remaining capacity preferentially allocated to Review demand of neurology care				
	Simple difference	10%	20%	30%	40%	50%
Supply vs demand						
Initial met	172,099.08	17,209.91	34,419.82	51,629.72	68,839.63	86,049.54
Initial not met	0.00	154,889.17	137,679.26	120,469.35	103,259.45	86,049.54
Review met	878,180.4	1,302,400.46	1,285,130.92	1,267,861.37	1,250,591.83	1,233,322.29
Review not met	-1,322,515.80	-898,295.74	-915,565.28	-932,834.83	-950,104.37	-967,373.91
Durational supply vs demand						
Initial met	134,447.29	13,444.73	26,889.46	40,334.19	53,778.92	67,223.64
Initial not met	0.00	121,002.56	107,557.83	94,113.10	80,668.37	67,223.64

Review met	342,490.36	673,407.52	659,962.79	646,518.06	633,073.33	619,628.60
Review not met	-538,385.39	-207,468.23	-220,912.96	-234,357.69	-247,802.41	-261,247.14

References

1. Dubey D, Pittock SJ, Kelly CR, et al. Autoimmune encephalitis epidemiology and a comparison to infectious encephalitis. *Annals of neurology* 2018;83(1):166-77. doi: 10.1002/ana.25131 [published Online First: 2018/01/03]
2. Feigin VL, Vos T, Alahdab F, et al. Burden of Neurological Disorders Across the US From 1990-2017: A Global Burden of Disease Study. *JAMA neurology* 2021;78(2):165-76. doi: 10.1001/jamaneurol.2020.4152 [published Online First: 2020/11/03]
3. Dewan MC, Rattani A, Gupta S, et al. Estimating the global incidence of traumatic brain injury. *Journal of neurosurgery* 2018:1-18. doi: 10.3171/2017.10.Jns17352 [published Online First: 2018/04/28]
4. Frost RB, Farrer TJ, Primosch M, et al. Prevalence of traumatic brain injury in the general adult population: a meta-analysis. *Neuroepidemiology* 2013;40(3):154-9. doi: 10.1159/000343275 [published Online First: 2012/12/22]
5. Broers MC, Bunschoten C, Nieboer D, et al. Incidence and Prevalence of Chronic Inflammatory Demyelinating Polyradiculoneuropathy: A Systematic Review and Meta-Analysis. *Neuroepidemiology* 2019;52(3-4):161-72. doi: 10.1159/000494291 [published Online First: 2019/01/23]
6. Fiest KM, Sauro KM, Wiebe S, et al. Prevalence and incidence of epilepsy: A systematic review and meta-analysis of international studies. *Neurology* 2017;88(3):296-303. doi: 10.1212/wnl.0000000000003509 [published Online First: 2016/12/18]
7. Garrett AR, Hodges SD, Stahlman S. Epidemiology of functional neurological disorder, active component, U.S. Armed Forces, 2000-2018. *Msmr* 2020;27(7):16-22. [published Online First: 2020/07/30]
8. Sejvar JJ, Baughman AL, Wise M, et al. Population incidence of Guillain-Barré syndrome: a systematic review and meta-analysis. *Neuroepidemiology* 2011;36(2):123-33. doi: 10.1159/000324710 [published Online First: 2011/03/23]

9. Bragazzi NL, Kolahi AA, Nejadghaderi SA, et al. Global, regional, and national burden of Guillain-Barré syndrome and its underlying causes from 1990 to 2019. *Journal of neuroinflammation* 2021;18(1):264. doi: 10.1186/s12974-021-02319-4 [published Online First: 2021/11/13]
10. Lyngberg AC, Rasmussen BK, Jørgensen T, et al. Incidence of primary headache: a Danish epidemiologic follow-up study. *American journal of epidemiology* 2005;161(11):1066-73. doi: 10.1093/aje/kwi139 [published Online First: 2005/05/20]
11. Burch RC, Buse DC, Lipton RB. Migraine: Epidemiology, Burden, and Comorbidity. *Neurologic clinics* 2019;37(4):631-49. doi: 10.1016/j.ncl.2019.06.001 [published Online First: 2019/09/30]
12. GBD 2016 Motor Neuron Disease Collaborators. Global, regional, and national burden of motor neuron diseases 1990-2016: a systematic analysis for the Global Burden of Disease Study 2016. *The Lancet Neurology* 2018;17(12):1083-97. doi: 10.1016/s1474-4422(18)30404-6 [published Online First: 2018/11/10]
13. Campbell JA, Simpson S, Jr., Ahmad H, et al. Change in multiple sclerosis prevalence over time in Australia 2010-2017 utilising disease-modifying therapy prescription data. *Multiple sclerosis (Houndmills, Basingstoke, England)* 2019;26(11):1315-28. doi: 10.1177/1352458519861270 [published Online First: 2019/07/28]
14. Carr AS, Cardwell CR, McCarron PO, et al. A systematic review of population based epidemiological studies in Myasthenia Gravis. *BMC neurology* 2010;10:46. doi: 10.1186/1471-2377-10-46 [published Online First: 2010/06/23]
15. Meyer A, Meyer N, Schaeffer M, et al. Incidence and prevalence of inflammatory myopathies: a systematic review. *Rheumatology (Oxford, England)* 2015;54(1):50-63. doi: 10.1093/rheumatology/keu289 [published Online First: 2014/07/30]
16. Satizabal CL, Beiser AS, Chouraki V, et al. Incidence of Dementia over Three Decades in the Framingham Heart Study. *The New England journal of medicine* 2016;374(6):523-32. doi: 10.1056/NEJMoa1504327 [published Online First: 2016/02/11]
17. Akushevich I, Yashkin AP, Kravchenko J, et al. Time Trends in the Prevalence of Neurocognitive Disorders and Cognitive Impairment in the United States: The Effects of Disease Severity and Improved Ascertainment. *Journal of Alzheimer's disease : JAD* 2018;64(1):137-48. doi: 10.3233/jad-180060 [published Online First: 2018/06/06]
18. Braithwaite T, Subramanian A, Petzold A, et al. Trends in Optic Neuritis Incidence and Prevalence in the UK and Association With Systemic and Neurologic Disease. *JAMA neurology* 2020;77(12):1514-23. doi: 10.1001/jamaneurol.2020.3502 [published Online First: 2020/10/06]
19. Dieleman JP, Kerklaan J, Huygen F, et al. Incidence rates and treatment of neuropathic pain conditions in the general population. *Pain* 2008;137(3):681-88. doi: 10.1016/j.pain.2008.03.002 [published Online First: 2008/04/29]
20. Yawn BP, Wollan PC, Weingarten TN, et al. The prevalence of neuropathic pain: clinical evaluation compared with screening tools in a community population. *Pain medicine (Malden, Mass)* 2009;10(3):586-93. doi: 10.1111/j.1526-4637.2009.00588.x [published Online First: 2009/04/01]
21. Ou Z, Pan J, Tang S, et al. Global Trends in the Incidence, Prevalence, and Years Lived With Disability of Parkinson's Disease in 204 Countries/Territories From 1990 to 2019. *Frontiers in public health* 2021;9:776847. doi: 10.3389/fpubh.2021.776847 [published Online First: 2021/12/25]
22. Asplund M, Nilsson M, Jacobsson A, et al. Incidence of traumatic peripheral nerve injuries and amputations in Sweden between 1998 and 2006. *Neuroepidemiology* 2009;32(3):217-28. doi: 10.1159/000197900 [published Online First: 2009/01/29]

23. Hanewinckel R, van Oijen M, Ikram MA, et al. The epidemiology and risk factors of chronic polyneuropathy. *European journal of epidemiology* 2016;31(1):5-20. doi: 10.1007/s10654-015-0094-6 [published Online First: 2015/12/25]
24. Kruja J, Beghi E, Zerbi D, et al. High prevalence of major neurological disorders in two Albanian communities: results of a door-to-door survey. *Neuroepidemiology* 2012;38(3):138-47. doi: 10.1159/000336348 [published Online First: 2012/03/22]
25. Sleep Health Foundation. Rise and try to shine: The social and economic cost of sleep disorders in Australia, 2021.
26. Rogers AE, Stahlman S, Hunt DJ, et al. Obstructive sleep apnea and associated attrition, active component, U.S. Armed Forces, January 2004-May 2016. *Msmr* 2016;23(10):2-11. [published Online First: 2016/10/30]
27. Perlis ML, Vargas I, Ellis JG, et al. The Natural History of Insomnia: the incidence of acute insomnia and subsequent progression to chronic insomnia or recovery in good sleeper subjects. *Sleep* 2020;43(6) doi: 10.1093/sleep/zsz299 [published Online First: 2019/12/19]
28. O'Connor P. Incidence and patterns of spinal cord injury in Australia. *Accident; analysis and prevention* 2002;34(4):405-15. doi: 10.1016/s0001-4575(01)00036-7 [published Online First: 2002/06/18]
29. GBD 2016 Motor Neuron Disease Collaborators. Global, regional, and national burden of stroke and its risk factors, 1990-2019: a systematic analysis for the Global Burden of Disease Study 2019. *The Lancet Neurology* 2021;20(10):795-820. doi: 10.1016/s1474-4422(21)00252-0 [published Online First: 2021/09/07]
30. Bhat A, Naguwa S, Cheema G, et al. The epidemiology of transverse myelitis. *Autoimmunity reviews* 2010;9(5):A395-9. doi: 10.1016/j.autrev.2009.12.007 [published Online First: 2009/12/29]
31. Laakso SM, Hekali O, Kurdo G, et al. Trigeminal neuralgia in multiple sclerosis: Prevalence and association with demyelination. *Acta neurologica Scandinavica* 2020;142(2):139-44. doi: 10.1111/ane.13243 [published Online First: 2020/03/19]
32. Manzoni GC, Torelli P. Epidemiology of typical and atypical craniofacial neuralgias. *Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology* 2005;26 Suppl 2:s65-7. doi: 10.1007/s10072-005-0410-0 [published Online First: 2005/06/01]
33. Royal Australasian College of Physicians. RACP Member Statistics and Insights, 2020. Sydney, 2020.
34. Royal Australasian College of Physicians. RACP Member Statistics and Insights, 2019. Sydney, 2019.